Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis
The Journal of Infection in Developing Countries · 2025
DOI: 10.3855/jidc.21109 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Joyce Sanyour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (U…. Hauptthemen laut MEDLINE: Colitis, Immune Checkpoint Inhibitors, Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized. The potential role of viral reactivation in exacerbating these toxicities is not well established. Cases Presentation: We report two cases of patients with solid tumors treated with ICIs who developed severe, refractory immune-related colitis. Extensive evaluation revealed markedly elevated CMV and EBV viral loads in colonic biopsies, confirmed by histopathology. Both patients showed significant clinical and endoscopic improvement following antiviral therapy with ganciclovir, highlighting the role of CMV and EBV in modulating the severity of ICI-induced colitis.
Conclusions
CMV and EBV reactivation may contribute to the persistence or worsening of ICI-induced colitis. Early recognition and treatment of viral reactivation in patients with irAEs may improve outcomes. Clinical judgment and serial viral monitoring are essential for guiding management decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
- Infectious Diseases Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
- Medical Oncology Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
- Histopathology Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
- Laboratory Medicine, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
Zitieren
APA
Sanyour, J., Awada, B., Mattar, A., Matar, R., Yaqoub, N., Al Haddabi, I., Al-Baimani, K., & Qarshoubi, I. (2025). Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.21109
Vancouver
Sanyour J, Awada B, Mattar A, Matar R, Yaqoub N, Al Haddabi I, et al. Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.21109
BibTeX
@article{Sanyour2025,
author = {Sanyour, Joyce and Awada, Bassem and Mattar, Ahmad and Matar, Rasha and Yaqoub, Nausheen and Al Haddabi, Ibrahim and Al-Baimani, Khalid and Qarshoubi, Issa},
title = {Cytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis},
journal = {The Journal of Infection in Developing Countries},
year = {2025},
doi = {10.3855/jidc.21109}
}
EUVIMED